Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.

@article{WernerWasik1996FinalRO,
  title={Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.},
  author={Maria Werner-Wasik and Charles B. Scott and Diana Furst Nelson and Laurie E. Gaspar and Kevin J. Murray and Jim Fischbach and James S. Nelson and Alan S. Weinstein and Walter J. Curran},
  journal={Cancer},
  year={1996},
  volume={77 8},
  pages={1535-43}
}
BACKGROUND Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas has yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose without increasing normal tissue late effects, whereas accelerated hyperfractionated radiation therapy (AHF) may minimize tumor repopulation by shortening overall treatment time. The Radiation Therapy Oncology… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…